NervGen Pharma Corp.
NGENHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeNervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma. Valued at $153.8M, NGEN is a micro-cap name in its sector. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study.
Market Cap
$153.8M
Beta
0.82
P/E (TTM)
—
P/E (Fwd)
-4.22
EPS (TTM)
$-0.57
EPS (Fwd)
$-0.34
ROE
-96.8%
ROA
-38.0%
Cash
$86.8M
Total Debt
$0
Free CF
$8.9M
52W Change
-47.8%
Annual Financials
Cash vs Debt
Where NGEN stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, NGEN finished 39.13% below its 150-day moving average ($2.53) and 49.34% below its 200-day moving average ($3.04). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NGEN overbought or oversold?
At the October 20, 2026 close, NGEN's RSI(14) was 18.9, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
NervGen Pharma Corp. reports $86.8M in cash and $0 in total debt. Free cash flow comes in at $8.9M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of -96.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
As with any equity investment, NGEN carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence NervGen Pharma Corp.'s trajectory.